Booster Effectiveness Charts

Important update: Healthcare facilities

CDC has updated select ways to operate healthcare systems effectively in response to COVID-19 vaccination. Learn more

Find the latest information:
Recommendations for Fully Vaccinated People
COVID-19 Homepage

UPDATE

Given new evidence on the B.1.617.2 (Delta) variant, CDC has updated the guidance for fully vaccinated people. CDC recommends universal indoor masking for all teachers, staff, students, and visitors to K-12 schools, regardless of vaccination status. Children should return to full-time in-person learning in the fall with layered prevention strategies in place.

UPDATE

The White House announced that vaccines will be required for international travelers coming into the United States, with an effective date of November 8, 2021. For purposes of entry into the United States, vaccines accepted will include FDA approved or authorized and WHO Emergency Use Listing vaccines. More information is available here.

UPDATE

Travel requirements to enter the United States are changing, starting November 8, 2021. More information is available here.

Español | Other Languages

Infection – 3 doses vs. 2 doses

Booster Vaccine Effectiveness Against Infection (3 doses vs. 2 doses) Data Table
Data as of 05/04/2022
Platform	Outcome	Age Group	Product	Schedule	Variant	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
ICATT	Symptomatic infection	.	mRNA	3 vs. 2	Delta	12/01/21	12/31/21	12/15/21	84	83	86	VE (3 vs. 2 Doses) Against Infection
ICATT	Symptomatic infection	.	mRNA	3 vs. 2	Omicron	12/01/21	12/31/21	12/15/21	66	64	68	VE (3 vs. 2 Doses) Against Infection
ICATT	Symptomatic infection	.	All vaccines	3 vs. 2	Omicron	01/01/22	01/31/22	01/15/22	61.93	60.90	62.92	VE (3 vs. 2 Doses) Against Infection
ICATT	Symptomatic infection	.	All vaccines	3 vs. 2	Omicron	02/01/22	02/28/22	02/14/22	56.19	55.06	57.30	VE (3 vs. 2 Doses) Against Infection
ICATT	Symptomatic infection	.	All vaccines	3 vs. 2	Omicron	03/01/22	03/31/22	03/15/22	33.34	29.99	36.52	VE (3 vs. 2 Doses) Against Infection

Dates are approximate

Download Data [6 KB, XLSX]

Embed Code:

<!– Markup for HTML (Booster Effectiveness Charts | CDC) –><div class=’rid_75f75656_501196′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’501196′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart01′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/501196/noscript’>source URL</a>.</noscript>

Infection – 3 doses vs. 0 doses

Booster Vaccine Effectiveness Against Infection (3 doses vs. 0 doses) Data Table
Data as of 03/28/2022
Platform	Outcome	Age Group	Product	Schedule	Variant	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
ICATT	Symptomatic infection	.	mRNA	3 vs. 0	Delta	12/01/21	12/31/21	12/15/21	93.5	92.9	94.1	VE (3 vs. 0 Doses) Against Infection
ICATT	Symptomatic infection	.	mRNA	3 vs. 0	Omicron	12/01/21	12/31/21	12/15/21	67.0	65.0	69.0	VE (3 vs. 0 Doses) Against Infection
ICATT	Symptomatic infection	.	mRNA	3 vs. 0	Omicron	1/01/22	1/31/22	1/15/22	64.7	64.1	65.2	VE (3 vs. 0 Doses) Against Infection
ICATT	Symptomatic infection	.	mRNA	3 vs. 0	Omicron	2/01/22	02/28/21	2/14/22	51.7	50.5	52.9	VE (3 vs. 0 Doses) Against Infection

Dates are approximate

Download Data [6 KB, XLSX]

Embed Code:

<!– Markup for HTML (Booster Effectiveness Charts | CDC) –><div class=’rid_02d0cc7b_501198′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’501198′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart02′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/501198/noscript’>source URL</a>.</noscript>

Hospitalization – 3 doses vs. 0 doses

Booster Vaccine Effectiveness Against Hospitalization (3 doses vs. 0 doses) Data Table
Data as of 05/04/2022
Platform	Outcome	Age Group	Product	Schedule	Variant	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	3 vs. 0	Delta	08/01/21	12/01/21	10/01/21	94	91	96	VE (3 vs. 0 Doses) Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	3 vs. 0	Omicron	01/01/22	01/31/22	01/15/22	87	79	92	VE (3 vs. 0 Doses) Against Hospitalization
IVY	Hospitalization (SARS-CoV-2-pos)	18 years and older	All vaccines	3 vs. 0	Omicron	02/01/22	03/31/22	3/01/22	78	68	85	VE (3 vs. 0 Doses) Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	3 vs. 0	Delta	08/01/21	12/31/21	10/04/21	95	95	96	VE (3 vs. 0 Doses) Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	3 vs. 0	Omicron	12/01/21	12/31/21	12/15/21	90	80	94	VE (3 vs. 0 Doses) Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 years and older	mRNA	3 vs. 0	Omicron	01/01/22	01/31/22	01/15/22	88	86	90	VE (3 vs. 0 Doses) Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	All vaccines	3 vs. 0	Omicron	01/01/22	02/28/22	02/01/22	84	81	86	VE (3 vs. 0 Doses) Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	18 – 64 years	All vaccines	3 vs. 0	Omicron	03/01/22	03/31/22	03/15/22	71	46	84	VE (3 vs. 0 Doses) Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	65 years and older	All vaccines	3 vs. 0	Omicron	01/01/22	02/28/22	02/01/22	89	87	90	VE (3 vs. 0 Doses) Against Hospitalization
VISION	Hospitalization (SARS-CoV-2-pos)	65 years and older	All vaccines	3 vs. 0	Omicron	03/01/22	03/31/22	03/15/22	86	77	91	VE (3 vs. 0 Doses) Against Hospitalization

Dates are approximate

Download Data [6 KB, XLSX]

Embed Code:

<!– Markup for HTML (Booster Effectiveness Charts | CDC) –><div class=’rid_4f3f8a09_501199′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’501199′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart03′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/501199/noscript’>source URL</a>.</noscript>

Infection – 3 doses vs. 2 doses (By Vaccine Product (ICATT) )

Booster Vaccine Effectiveness Against Infection by Vaccine Product (3 doses vs. 2 doses) Data Table
Data as of 02/10/2022
Platform	Outcome	Age Group	Product	Schedule	Variant	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
ICATT	Symptomatic infection	.	Pfizer	3 vs. 2	Delta	12/01/21	12/31/21	12/15/21	83	81	84	VE (3 vs. 2 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Moderna	3 vs. 2	Delta	12/01/21	12/31/21	12/17/21	87	85	89	VE (3 vs. 2 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Pfizer	3 vs. 2	Omicron	12/01/21	12/31/21	12/15/21	65	63	68	VE (3 vs. 2 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Moderna	3 vs. 2	Omicron	12/01/21	12/31/21	12/17/21	69	66	72	VE (3 vs. 2 Doses) Against Infection by Product

Dates are approximate

Download Data [7 KB, XLSX]

Embed Code:

<!– Markup for HTML (Booster Effectiveness Charts | CDC) –><div class=’rid_9a18481b_501200′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’501200′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart04′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/501200/noscript’>source URL</a>.</noscript>

Infection – 3 doses vs. 0 doses (By Vaccine Product (ICATT) )

Booster Vaccine Effectiveness Against Infection by Vaccine Product (3 doses vs. 0 doses) Data Table
Data as of 03/28/2022
Platform	Outcome	Age Group	Product	Schedule	Variant	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
ICATT	Symptomatic infection	.	Pfizer	3 vs. 0	Delta	12/01/21	12/31/21	12/15/21	92.3	91.4	93.0	VE (3 vs. 0 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Moderna	3 vs. 0	Delta	12/01/21	12/31/21	12/17/21	95.5	94.7	96.2	VE (3 vs. 0 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Pfizer	3 vs. 0	Omicron	12/01/21	12/31/21	12/15/21	65.0	62.0	68.0	VE (3 vs. 0 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Pfizer	3 vs. 0	Omicron	01/01/22	01/31/22	01/15/22	62.3	61.6	63.0	VE (3 vs. 0 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Pfizer	3 vs. 0	Omicron	02/01/22	02/28/22	02/14/22	49.2	47.7	50.6	VE (3 vs. 0 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Moderna	3 vs. 0	Omicron	12/01/21	12/31/21	12/17/21	72.0	69.0	74.0	VE (3 vs. 0 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Moderna	3 vs. 0	Omicron	01/01/22	01/31/22	01/15/22	67.5	66.8	68.2	VE (3 vs. 0 Doses) Against Infection by Product
ICATT	Symptomatic infection	.	Moderna	3 vs. 0	Omicron	02/01/22	02/28/22	02/14/22	56.2	54.8	57.7	VE (3 vs. 0 Doses) Against Infection by Product

Dates are approximate

Download Data [7 KB, XLSX]

Embed Code:

<!– Markup for HTML (Booster Effectiveness Charts | CDC) –><div class=’rid_d6b80b99_501214′ data-apiroot=’//tools.cdc.gov/api’ data-mediatype=’html’ data-mediaid=’501214′ data-stripscripts=’true’ data-stripanchors=’false’ data-stripimages=’false’ data-stripcomments=’true’ data-stripstyles=’true’ data-cssclasses=’chart05′ data-ids=” data-xpath=” data-oe=’utf-8′ data-of=’xhtml’ data-ns=’cdc’ data-postprocess=” data-nw=’true’ data-iframe=’true’ data-cdc-widget=’syndicationIframe’ data-apiembedsrc=’//tools.cdc.gov/api/embed/html/js/embed-2.0.3.js’ data-iframeembedsrc=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’></div><script src=’//tools.cdc.gov/TemplatePackage/contrib/widgets/tp-widget-external-loader.js’ ></script><noscript>You need javascript enabled to view this content or go to <a href=’//tools.cdc.gov/api/v2/resources/media/501214/noscript’>source URL</a>.</noscript>